JP Morgan Maintains Emergent Biosolutions Inc to Overweight with Price Target $36.00

Brokerage firm JP Morgan Maintains its rating on Emergent Biosolutions Inc(NYSE:EBS). In a research note issued to the investors, the brokerage major Lowers the price-target to $36.00 per share. The shares have been rated Overweight. The rating by JP Morgan was issued on Aug 5, 2016.

Emergent Biosolutions Inc (EBS) made into the market gainers list on Wednesdays trading session with the shares advancing 1.28% or 0.34 points. Due to strong positive momentum, the stock ended at $26.9, which is also near the day’s high of $26.91. The stock began the session at $26.58 and the volume stood at 10,08,511 shares. The 52-week high of the shares is $41.914425 and the 52 week low is $25.509433. The company has a current market capitalization of $1,088 M and it has 4,04,58,718 shares in outstanding.

Emergent Biosolutions Inc(EBS) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $101.49M. Analysts had an estimated revenue of $111.20M. Earnings per share were $-0.18. Analysts had estimated an EPS of $-0.17.

Several Insider Transactions has been reported to the SEC. On Jun 7, 2016, George A Joulwan (director) sold 4,700 shares at $44.12 per share price.Also, On Jun 3, 2016, Daniel Abdun-nabi (President & CEO) sold 8,699 shares at $43.74 per share price.On May 27, 2016, Fuad El-hibri (Chairman) sold 9,835 shares at $43.50 per share price, according to the Form-4 filing with the securities and exchange commission.

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *